Assessment of the stability of dalteparin sodium in prepared syringes for up to thirty days: An in vitro study

Clinical Therapeutics

Volumn 25, Issue 4, 2003, Pages 1219-1225

  Laposata, Michael ^a   Johnson, Stephen M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Anti factor Xa; Anticoagulants; Dalteparin; Deep vein thrombosis; Low molecular weight heparin; Stability; Storage; Syringes

Indexed keywords

BLOOD CLOTTING FACTOR 10A; DALTEPARIN; PLASTIC;

ARTICLE; DOSE CALCULATION; DRUG ACTIVITY; DRUG STABILITY; DRUG STORAGE; FREEZING; IN VITRO STUDY; MOLECULAR WEIGHT; ROOM TEMPERATURE; SYRINGE; TIME;

EID: 0038070280     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80078-4     Document Type: Article

References (13)

1. Bergqvist D. The postdischarge risk of venous thromboembolism after hip replacement. The role of prolonged prophylaxis. Drugs. 1996;55(Suppl 7):5-59.
2. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-681.
3. Dedden P, Chang B, Nagel D. Pharmacy-managed program for home treatment of deep-vein thrombosis with enoxaparin. Am J Health Syst Pharm. 1997;54:1968-1972.
4. Martineau P, Tawil N. Low-molecular-weight heparins in the treatment of deep vein thrombosis. Ann Pharmacother. 1998;32:588-601.
5. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337:688-698.
6. Chaffee BJ. Low-molecular-weight heparins for treatment of deep vein thrombosis. Am J Health Syst Pharm. 1997;54:1995-1999.
7. Siragusa S, Cosmi B, Piovella F, et al. Low-molecular-weight heparins and unfracdonated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis. Am J Med. 1996;100:269-277.
8. Charland SL, Davis DD, Tillman DJ. Activity of enoxaparin sodium in tuberculin syringes for 10 days. Am J Health Syst Pharm. 1998;55:1296-1298.
9. Frydman A. Low-molecular-weight heparins: An overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996:26(Suppl 2):24-28.
10. Hamilton MA, Stang L, Etches-Wai S, et al. Stability of low molecular weight heparins (LMWH's) stored in plastic syringes. Blood. 2000;96:652a. Abstract.
11. Koopman MM, Prandoni P, Piovella F, et al, for the Tasman Study Group. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 1996;334:682-687.
12. Wells PS, Kovacs MJ, Bormanis J, et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: A comparison of patient self-injection with homecare injection. Arch Intern Med. 1998;158:1809-1812.
13. Harrison L, McGinnis J, Crowther M, et al. Assessment of outpatient treatment of deep-vein thrombosis with low molecular-weight heparin. Arch Intern Med. 1998;158:2001-2003.